Hytrin: Effective Blood Pressure and BPH Symptom Management
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.95 | $57.26 (0%) | 🛒 Add to cart |
| 90 | $0.86 | $85.89 $77.36 (10%) | 🛒 Add to cart |
| 120 | $0.82 | $114.53 $98.45 (14%) | 🛒 Add to cart |
| 180 | $0.76 | $171.79 $137.63 (20%) | 🛒 Add to cart |
| 270 | $0.74 | $257.68 $198.91 (23%) | 🛒 Add to cart |
| 360 | $0.73
Best per pill | $343.58 $261.20 (24%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.44 | $73.34 (0%) | 🛒 Add to cart |
| 60 | $1.91 | $146.67 $114.53 (22%) | 🛒 Add to cart |
| 90 | $1.73 | $220.01 $155.72 (29%) | 🛒 Add to cart |
| 120 | $1.64 | $293.35 $196.91 (33%) | 🛒 Add to cart |
| 180 | $1.55 | $440.02 $279.28 (37%) | 🛒 Add to cart |
| 270 | $1.50
Best per pill | $660.03 $404.86 (39%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.98 | $89.41 (0%) | 🛒 Add to cart |
| 60 | $2.24 | $178.82 $134.62 (25%) | 🛒 Add to cart |
| 90 | $2.00 | $268.23 $179.83 (33%) | 🛒 Add to cart |
| 120 | $1.88 | $357.64 $226.04 (37%) | 🛒 Add to cart |
| 180 | $1.76 | $536.47 $316.45 (41%) | 🛒 Add to cart |
| 270 | $1.68
Best per pill | $804.70 $453.08 (44%) | 🛒 Add to cart |
Synonyms
| |||
Hytrin (terazosin hydrochloride) is an alpha-1 adrenergic blocker prescription medication clinically proven to manage hypertension and benign prostatic hyperplasia (BPH). Developed to provide dual therapeutic action, it works by relaxing blood vessels and prostate/bladder neck muscles, facilitating easier blood flow and urination. With its well-established efficacy profile and once-daily dosing convenience, Hytrin remains a trusted option for physicians seeking to improve cardiovascular and urinary parameters in appropriate patient populations. This comprehensive guide details its pharmacological properties, clinical applications, and essential safety information.
Features
- Active ingredient: Terazosin hydrochloride
- Available in tablet formulations (1mg, 2mg, 5mg, 10mg)
- Alpha-1 selective adrenergic receptor blockade
- Once-daily dosing regimen
- Bioavailability approximately 90% when taken orally
- Peak plasma concentration reached within 1-2 hours
- Elimination half-life of approximately 12 hours
- Hepatic metabolism via cytochrome P450 system
- Primarily renal excretion pathway
Benefits
- Effectively lowers both systolic and diastolic blood pressure through vascular smooth muscle relaxation
- Significantly improves urinary flow rates and reduces BPH symptoms including nocturia, hesitancy, and incomplete bladder emptying
- Single daily dosing enhances medication adherence and convenience for patients
- Demonstrated long-term safety profile with extensive clinical documentation
- May improve lipid profiles with modest reductions in total cholesterol and LDL levels
- Provides symptomatic relief without affecting prostate size through mechanical obstruction reduction
Common use
Hytrin is primarily prescribed for the management of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. Additionally, it is indicated for the symptomatic treatment of benign prostatic hyperplasia (BPH) in patients with demonstrated urinary obstruction and irritative symptoms. Physicians may initiate therapy for both conditions simultaneously when clinically appropriate, though careful titration is required. The medication is typically used in adult populations, with special consideration given to elderly patients who may experience enhanced sensitivity to its effects.
Dosage and direction
Initial dosing for hypertension typically begins with 1mg at bedtime, with gradual titration to 2mg, 5mg, and then 10mg once daily as needed for blood pressure control. For BPH treatment, starting dose is 1mg at bedtime, with upward titration to 2mg, 5mg, or 10mg once daily based on symptomatic response and tolerability. Maximum recommended dose is 20mg daily. Dose adjustments should occur at approximately 2-week intervals. Administration with food does not significantly affect bioavailability but may reduce potential gastrointestinal discomfort. The bedtime administration is particularly recommended during initial titration to minimize first-dose hypotensive effects.
Precautions
Patients should be advised about the potential for syncope and symptomatic hypotension, particularly with the first dose or during dosage adjustments. Caution is warranted when rising from sitting or lying positions due to possible orthostatic hypotension. Regular monitoring of blood pressure is essential, especially during initial treatment phases. Hepatic impairment may require dosage adjustment due to reduced metabolism. Patients with renal impairment do not typically require dosage modification as terazosin is primarily metabolized hepatically. Ophthalmological monitoring is recommended in patients considering cataract surgery due to the potential for intraoperative floppy iris syndrome.
Contraindications
Hytrin is contraindicated in patients with known hypersensitivity to terazosin hydrochloride or any component of the formulation. It should not be administered concurrently with other alpha-adrenergic blocking agents due to potential additive effects. Use is contraindicated in patients with severe hepatic impairment where drug metabolism may be significantly compromised. The medication is not recommended for pediatric patients due to insufficient safety and efficacy data in this population. Patients with a history of orthostatic hypotension or syncopal episodes should be carefully evaluated before initiation.
Possible side effect
Common adverse reactions include dizziness (8.9-19.3%), asthenia (5.5-11.3%), nasal congestion (5.9%), peripheral edema (4.9%), and somnolence (3.8-5.4%). Postural hypotension occurs in approximately 3.9% of patients. Less frequently reported effects include palpitations (4.3%), nausea (4.4%), blurred vision (1.6-4.0%), and syncope (0.6-1.3%). Sexual side effects including impotence and decreased libido occur in approximately 1.6% of patients. Most adverse reactions are dose-dependent and tend to diminish with continued therapy. Serious but rare side effects include priapism (requiring immediate medical attention) and angina exacerbation.
Drug interaction
Concomitant use with other antihypertensive agents may produce additive hypotensive effects. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) may significantly potentiate hypotensive effects. Nonsteroidal anti-inflammatory drugs may reduce the antihypertensive efficacy of terazosin. Beta-blockers and diuretics may enhance first-dose hypotensive response. Estrogens may reduce antihypertensive effectiveness through fluid retention mechanisms. Concomitant use with other alpha-adrenergic blockers is contraindicated. Medications that inhibit cytochrome P450 3A4 may increase terazosin concentrations.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Patients should never double the dose to make up for a missed administration. If multiple doses are missed, consultation with a healthcare provider is recommended before resuming therapy, as dose retitration may be necessary to prevent exaggerated first-dose effects. Consistent daily administration at approximately the same time maintains stable plasma concentrations and optimal therapeutic effect.
Overdose
Acute overdose may manifest as pronounced hypotension, dizziness, lightheadedness, and syncope. Supportive care including supine positioning with legs elevated is indicated. Volume expansion with intravenous fluids should be initiated for significant hypotension. Vasopressors may be required for refractory cases, with careful monitoring of blood pressure and cardiac function. Gastric lavage may be considered if ingestion occurred within a few hours. Hemodialysis is not effective due to high protein binding. Symptomatic and supportive measures should be maintained until stabilization is achieved.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Protect from light and moisture. Keep in original container with tight closure. Do not store in bathroom areas where humidity fluctuations may occur. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Properly dispose of unused medication through take-back programs or according to FDA guidelines.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Hytrin is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and patients should follow their physician’s specific instructions regarding use, dosage, and monitoring. This summary does not include all possible information about this medication and should not be used to make treatment decisions without consulting a healthcare provider.
Reviews
Clinical studies demonstrate that approximately 70% of hypertensive patients achieve blood pressure control with terazosin monotherapy. In BPH trials, International Prostate Symptom Scores typically improve by 30-40% from baseline. Patient satisfaction surveys indicate improved quality of life measures related to both cardiovascular and urinary symptoms. Long-term extension studies show maintained efficacy over 24+ months of treatment with consistent safety profile. Real-world evidence supports the effectiveness described in controlled clinical trials, with particular emphasis on the importance of proper dose titration to minimize initial side effects.